Adenocarcinoma — Trials

Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

9,705 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,753
Recruiting: 1,519
Ph III recruiting: 166
Growth YoY: +7.4%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,321)

clinicaltrialsPublishedShowing 701–750 of 1,897 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07417800	Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning	recruiting	—	11,000	Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER	1	Jun 10, 2026	clinicaltrials
NCT07517198	Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors	recruiting	Phase 1	40	Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.